A novel small molecule, HK-156, inhibits lipopolysaccharide-induced activation of NF-B signaling and improves survival in mouse models of sepsis

Acta Pharmacologica Sinica

Volumn 33, Issue 9, 2012, Pages 1204-1216

  Fang, Jian Ping ^a   Liu, Yang ^a   Li, Jie ^a   Liao, Wen Feng ^a   Hu, You Hong ^a   Ding, Kan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

HK 156; IKK ; lipopolysaccharide; monocyte; NF B; NF B inhibitor; p38; sepsis; TAK1

Indexed keywords

ACRYLAMIDE DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; HK 156; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG DNA BINDING; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL; SURVIVAL TIME; TRANSCRIPTION INITIATION;

ACRYLAMIDES; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTOXEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; NF-KAPPA B; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PYRIMIDINES; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 84866004756     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.56     Document Type: Article

References (50)

1. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-62.
2. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
3. Huxford T, Ghosh G. A structural guide to proteins of the NF-kappaB signaling module. Cold Spring Harb Perspect Biol 2009; 1: a000075.
4. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-66.
5. Yamamoto Y, Gaynor RB. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 2001; 1: 287-96. (Pubitemid 33773312)
6. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W, et al. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 2006; 25: 6781-99. (Pubitemid 44657852)
7. Dong J, Jimi E, Zeiss C, Hayden MS, Ghosh S. Constitutively active NF-kappaB triggers systemic TNFalpha-dependent infl ammation and localized TNFalpha-independent inflammatory disease. Genes Dev 2010; 24: 1709-17.
8. Ivanenkov YA, Balakin KV, Tkachenko SE. New approaches to the treatment of infl ammatory disease: focus on small-molecule inhibitors of signal transduction pathways. Drugs R D 2008; 9: 397-434.
9. O'Neill LA. Targeting signal transduction as a strategy to treat infl ammatory diseases. Nat Rev Drug Discov 2006; 5: 549-63. (Pubitemid 43971190)
10. Sarkar FH, Li Y, Wang Z, Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008; 27: 293-319.
11. Suffredini AF, Munford RS. Novel therapies for septic shock over the past 4 decades. JAMA 2011; 306: 194-9.
12. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-43. (Pubitemid 27343624)
13. Munford RS. Severe sepsis and septic shock: the role of gramnegative bacteremia. Annu Rev Pathol 2006; 1: 467-96.
14. Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and infl ammation. Am J Physiol Lung Cell Mol Physiol 2006; 290: L622-45. (Pubitemid 43738989)
15. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-51.
16. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005; 6: 1087-95. (Pubitemid 41541786)
17. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13: 85-94. (Pubitemid 32222977)
18. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.
19. Miggin SM, O'Neill LA. New insights into the regulation of TLR signaling. J Leukoc Biol 2006; 80: 220-6. (Pubitemid 44835495)
20. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009; 227: 248-63.
21. Wheeler DS, Zingarelli B, Wheeler WJ, Wong HR. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov 2009; 3: 96-112.
22. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 2006; 25: 6887-99. (Pubitemid 44657858)
23. Calzado MA, Bacher S, Schmitz ML. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 2007; 14: 367-76.
24. Bamborough P, Callahan JF, Christopher JA, Kerns JK, Liddle J, Miller DD, et al. Progress towards the development of anti-inflammatory inhibitors of IKKbeta. Curr Top Med Chem 2009; 9: 623-39.
25. Leon CG, Tory R, Jia J, Sivak O, Wasan KM. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res 2008; 25: 1751-61.
26. Barochia A, Solomon S, Cui X, Natanson C, Eichacker PQ. Eritoran tetra sodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011; 7: 479-94.
27. Abraham E. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 2003; 187: S364-9. (Pubitemid 36724510)
28. Robbins CS, Swirski FK. The multiple roles of monocyte subsets in steady state and infl ammation. Cell Mol Life Sci 2010; 67: 2685-93.
29. Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, et al. Comprehensive gene expression profi le of LPS-stimulated human monocytes by SAGE. Blood 2000; 96: 2584-91.
30. Palsson-McDermott EM, O'Neill LA. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004; 113: 153-62.
31. Landstrom M. The TAK1-TRAF6 signalling pathway. Int J Biochem Cell Biol 2010; 42: 585-9.
32. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-224.
33. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001; 98: 1429-39.
34. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993; 9: 317-43.
35. Secher T, Vasseur V, Poisson DM, Mitchell JA, Cunha FQ, Alves-Filho JC, et al. Crucial role of TNF receptors 1 and 2 in the control of polymicro bial sepsis. J Immunol 2009; 182: 7855-64.
36. Huang W, Tang Y, Li L. HMGB1, a potent proinfl ammatory cytokine in sepsis. Cytokine 2010; 51: 119-26.
37. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51. (Pubitemid 29329996)
38. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regula tion of IkappaB kinase activity through IKKbeta subunit phosphoryl ation. Science 1999; 284: 309-13.
39. Yang F, Tang E, Guan K, Wang CY. IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J Immunol 2003; 170: 5630-5. (Pubitemid 36617854)
40. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaBdependent gene expression. Nature 2003; 423: 659-63. (Pubitemid 36713228)
41. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expres sion. Nature 2003; 423: 655-9. (Pubitemid 36713227)
42. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of infl ammation. Nature 2005; 434: 1138-43. (Pubitemid 40663493)
43. Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, et al. Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict infl ammation and immunity. Cell 2007; 129: 903-14. (Pubitemid 46802704)
44. Liu B, Shuai K. Targeting the PIAS1 SUMO ligase pathway to control infl ammation. Trends Pharmacol Sci 2008; 29: 505-9.
45. Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing kinase activates IKKalpha by phosphorylation of Ser-176. Proc Natl Acad Sci U S A 1998; 95: 3792-7. (Pubitemid 28173208)
46. Wang RP, Zhang M, Li Y, Diao FC, Chen D, Zhai Z, et al. Differential regulation of IKK alpha-mediated activation of IRF3/7 by NIK. Mol Immunol 2008; 45: 1926-34.
47. Leung CH, Grill SP, Lam W, Gao W, Sun HD, Cheng YC. Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a non com peti tive manner. Mol Pharmacol 2006; 70: 1946-55. (Pubitemid 44771910)
48. Leung CH, Grill SP, Lam W, Han QB, Sun HD, Cheng YC. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol 2005; 68: 286-97. (Pubitemid 41058292)
49. Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, et al. Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. Eur J Pharmacol 2010; 643: 21-8.
50. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, et al. Antiinfl ammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000; 403: 103-8. (Pubitemid 30038530)